Bio-Gene Technology Ltd

Bio-Gene Technology Ltd

BGT · AU · Healthcare / Biotechnology

0.016AUD+0.00 (+6.67%)

Price History

Full chart

Market Stats

Previous Close0.015
Open0.016
Day Range0.016 – 0.016
52-Week Range0.016 – 0.045
Volume100.00K
Market Cap7.01M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta0.77
50-Day Avg0.0187
200-Day Avg0.026

About

Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with James Cook University for experiments demonstrating the value of pre-conditioning biomass prior to distillation; Cesar for assessing the insecticidal activity of its molecules against a range of insect species; Advanced Molecular Technologies; CSIRO for a chemistry development process; the Department of Agriculture and Fisheries, Queensland Government for assessing activity against grain storage pests; Eurofins; Grain Research Development Corporation; Pacific Discovery Services; Purdue University; Southern Cross University for chemical analysis of natural products; University of Florida; and University of Technology. It serves animal health, crop protection, grain storage, public health, and consumer applications. The company was incorporated in 1995 and is based in Melbourne, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Timothy Owen Grogan B.Sc., LLB
  • Employees0
  • Headquarters400 Collins Street, Melbourne, VIC, Australia, 3000, Australia
  • Websitehttps://www.bio-gene.com.au

Leadership

  • Mr. Timothy Owen Grogan B.Sc., LLBMD, CEO & Director
  • Mr. Drew Speedy AGIA, B.Bus, CPACFO & Company Secretary
  • Mr. Peter Donald May AFA1M, AFAIM, GAICD, M.B.A.Executive Director of Research & Development and Executive Director

Financials

Income Statement

Currency: AUD2014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue761.00K186.41K6.32K344.45K508.76K907.58K62.61K445.73K149.23K18.32K425.07K-
Growth (%)-+1215.79%+18541.50%-96.61%+5353.61%+47.70%+78.39%-93.10%+611.91%-66.52%-87.72%+2220.25%-
Cost of Revenue0015.81K443.52K98.89K106.64K267.13K173.20K267.14K313.27K319.77K245.78K42.00K
Gross Profit760170.61K-437.20K245.56K402.12K640.45K-110.59K178.59K-164.04K-301.45K-245.78K-42.00K
Gross Margin100.00%0.00%91.52%-6922.12%71.29%79.04%70.57%-176.64%40.07%-109.92%-1645.46%-57.82%-
Operating Expense137.54K178.70K679.54K718.11K3.55M2.59M2.80M2.49M3.59M3.46M2.76M2.82M3.36M
Operating Income-137.47K-178.70K-508.93K-1.16M-3.30M-2.19M-2.16M-2.60M-3.41M-3.63M-3.06M-3.07M-3.41M
Operating Margin-180880.26%-17870.20%-273.01%-18291.80%-958.28%-430.74%-238.09%-4149.40%-764.50%-2431.01%-16716.50%-721.51%-
EBITDA-136.51K-168.58K-493.08K-1.12M-3.13M-2.15M-2.10M-2.85M-2.92M-3.14M-2.97M-2.58M-3.36M
EBITDA Margin-179621.05%-16858.30%-264.51%-17656.06%-908.32%-421.78%-231.66%-4556.06%-655.91%-2101.73%-16239.02%-607.42%-
Net Income-87.31K-98.26K-322.52K-1.05M-2.83M-1.92M-1.93M-2.40M-2.91M-3.10M-2.41M-2.58M-2.33M
Net Income Margin-114876.32%-9826.10%-173.01%-16702.06%-822.49%-377.34%-212.99%-3827.29%-653.81%-2074.48%-13150.54%-608.01%-
R&D173.68K173.68K173.68K440.88K1.50M1.42M1.44M1.68M1.90M1.98M1.07M1.38M1.77M
R&D as % of Total Revenue228531.58%17368.40%93.17%6980.30%436.78%280.04%159.12%2677.55%425.97%1326.05%5842.85%324.57%-
Interest Expense0000001.23K33752.86K----
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.14%0.54%11.86%----

Balance Sheet

Currency: AUD2014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets290.99K435.36K856.35K9.45M7.67M5.56M6.57M5.00M7.30M3.84M3.16M2.15M2.61M
Total Liabilities955-383.00K373.94K759.59K613.61K567.29K754.57K1.03M613.88K368.45K522.98K519.76K
Total Equity290.03K435.36K473.35K9.07M6.91M4.95M6.00M4.25M6.27M3.22M2.79M1.63M2.09M
Cash51.26K208.81K101.65K8.79M6.71M4.50M5.52M3.93M6.34M2.99M2.21M1.14M1.94M
Total Debt---150.00K-150.00K161.66K150.00K---51.21K-
Net Debt-51.26K-208.81K-101.65K-8.64M-6.71M-4.50M-5.51M-3.93M-6.34M-2.99M-2.21M-1.14M-1.94M

Cash Flow

Currency: AUD2014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-47.57K-126.95K-419.35K-729.15K-2.37M-2.20M-1.64M-1.83M43.52K-3.28M-2.75M-2.54M-1.94M
Investing Cash Flow-1.53K-28.02K-28.02K-4.99K-309.50K-6.88K-3.03K-3.03K-6.84K0-5.70K0-
Financing Cash Flow57.50K284.50K340.20K3.49M6.53M1.17K2.67M239.88K4.41M-75.00K1.98M1.47M2.74M
Capital Expenditure1.53K28.02K28.02K4.99K239.50K2.68K3.03K3.03K6.84K05.70K01.94M
Free Cash Flow-49.09K-126.95K-447.37K-734.14K-2.61M-2.20M-1.64M-1.83M36.67K-3.28M-2.76M-2.54M-1.94M
Dividends Paid------13.77K11.66K75.00K----
FCF to OCF103.21%100.00%106.68%100.68%110.09%100.12%100.00%100.17%84.28%100.00%100.21%100.00%100.00%
Dividend Paid to FCF-------0.84%-0.64%204.50%----

Earnings

Report DateFeb 3, 2017Nov 27, 2017Feb 8, 2018Aug 22, 2018Feb 20, 2019Aug 22, 2019Feb 26, 2020Aug 26, 2020Feb 18, 2021Aug 26, 2021Feb 16, 2022Aug 15, 2022Feb 23, 2023Feb 27, 2025Aug 25, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.00-0.00--0.000.00
EPS Actual0.00-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01
Surprise---------------
Timing----------After-hoursAfter-hoursAfter-hours--

Key Statistics & Ratios

Market Cap7.01M
Enterprise Value6.26M
Trailing P/E0.00
Forward P/E0.00
Price / Sales6.50
Price / Book3.56
EPS-0.01
Book Value0.005
Revenue (TTM)1.08M
Gross Profit (TTM)-336.47K
EBITDA-2.31M
Profit Margin-216.04%
Operating Margin-86.87%
Return on Equity-125.40%
Return on Assets-61.86%
Shares Outstanding438.06M
Shares Float242.06M
Beta0.77
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%